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Abstract
Background: Studies found inconsistent frequencies of social anxiety disorder (SAD) in Parkinson’s disease (PD) (9.7%-50%). Previous reports did not test the 
impact of applying DSM-IV restrictive criteria that recommends the exclusion of secondary cases when diagnosing SAD in PD. Objective: Our aim is to estimate 
the frequency of social anxiety according to DSM-IV criteria and according to an inclusive broader approach. Methods: One hundred and ten PD patients were 
assessed for the presence of SAD using SCID-I, diagnosis of social anxiety were determined according to two different criteria: following and not following 
DSM-IV recommendation for exclusion of cases though to be secondary to a general medical condition. Results: SAD was present in 34 (31%) of patients, but 
17 (15.5%) were secondary to a general medical condition. Patients with SAD were significantly younger, had earlier disease onset, had more severe PD symp-
toms, and were more frequently depressed. There was no difference in demographic and clinical features between primary and secondary SAD. Discussion: We 
conclude that the use of different diagnostic criteria may have a massive impact in the estimation of frequency of SAD in PD.
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Introduction
Social anxiety disorder (SAD) is characterized by an abnormal fear 
and avoidance of scrutiny by others (DSM-IV)1. It has a point-
prevalence of 7.1%, and a life-time prevalence of up to 12.1%2. 
Anxiety disorders are known to be more prevalent in patients with 
Parkinson’s disease (PD) than in age and gender matched controls 
with similar debilitating diseases3. Despite the fact that anxiety has 
been largely studied in PD, only a few studies specifically addressed 
SAD in PD reporting widely variable prevalence of 9.7%4, 11.5%5, 
34%6 and 50%7.
One reason for this discrepancy is related to the lack on 
consensus on how to diagnose SAD in PD patients. DSM IV-TR 
recommends the exclusion of psychiatric symptoms that are 
likely attributable to a medical condition1 but it is possible that 
many clinically relevant cases are missed if the DSM-IV criteria 
is employed. Researchers who follow this recommendation often 
point out a lower frequencies of SAD in PD than researchers 
who does not (9.7%4, 11.5%5 and 17%6 versus 34%6 and 50%7 
respectively), nevertheless, except for a small study including only 
24 patients6, no work to date has directly compared the frequency 
of SAD in PD according to the two different criteria in the same 
PD sample. Although using DSM-IV recommendation may lead to 
underdiagnosis ignoring such criteria may result in misdiagnosis. 
Some PD symptoms overlap with anxiety symptoms (like tremor 
and dysautonomia) and the motor symptoms of PD (which include 
tremor and difficulty to perform motor tasks appropriately) cause 
worry and embarrassment, and many times withdraw from social 
situations. According to DSM-IV diagnosis of primary SAD should 
be made only for patients presenting all symptoms of social anxiety 
(criteria A to F) and that are not excluded by the G and H criteria. 
Patients whose phobic symptoms started close after a disease onset 
(criterion G) and those that fears or avoids situations that can be 
related to the presence of a physical condition (criterion H) should 
be considered secondary cases of SAD. 
We studied a sample of 110 PD patients aiming to compare 
the frequency of SAD in PD according to the two different criteria 
(using DSM-IV exclusion criteria and ignoring it) and to compare 
the clinical differences between primary and secondary SAD. We also 
tested the psychometric properties of a short screening instrument 
for SAD in PD. 
Methods
Study design
A cross-sectional descriptive study of a clinical sample of patients 
with PD was performed in a tertiary referral center in Brazil. 
Subjects
One hundred and ten PD patients who fulfilled Queen Square 
Brain Bank diagnostic criteria8 were screened for the presence of 
SAD. Patients were recruited from Movement Disorders Clinic of 
the Ribeirão Preto School of Medicine, Brazil. PD patients with 
dementia were not invited to participate. The presence of dementia 
was determined by direct interview with the patient and caregiver 
according to the DSM-IV diagnostic criteria. 
The local ethics committees of the three institutions involved 
in the study approved this study and all patients provided informed 
consent. 
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Clinical evaluation
An experienced psychiatrist (MHNC) conducted the psychiatric 
evaluation using a structured clinical interview (SCID-I)9 to 
diagnose current prevalence of SAD according to DSM IV-TR 
criteria. To fulfill criteria for SAD patients needed to present (1) 
persistent fear of one or more social or performance situations; 
(2) exposure to the feared situation almost invariably provokes 
anxiety; (3) the person recognizes that this fear is unreasonable 
or excessive; (4) the feared situations are avoided or endured with 
intense anxiety and distress; (5) symptoms interfere significantly 
with the person’s life or there is marked distress. All participants 
fulfilling such criteria were coded as SAD cases. Then SAD cases 
were coded in primary or secondary based on criteria G and H 
of the SCID. Following strictly DSM-IV criteria the diagnosis of 
primary SAD was made only in patients fulfilling G and H criteria. 
All other SAD cases were considered secondary SAD. 
Participants were also assessed using the previously validated 
Brazilian version of the Mini Social Phobia Inventory (Mini-SPIN), 
which is a self-report instrument to measure social anxiety symptoms10. 
Mini-SPIN is a very brief and easy to use instrument, it comprises only 
3 items derived from the Social Phobia Inventory. The respondent is 
asked to rate from 0 to 4 depending on how much they disagree or 
agree with the following 3 sentences: “Fear of embarrassment causes 
me to avoid doing things or speaking to people”; “I avoid activities in 
which I am the center of attention”; “Being embarrassed or looking 
stupid are among my worse fears”. The total score is the sum of scores 
in each of the three items, varying from 0 to 12. 
The presence of depressive symptoms was characterized using 
the 15-item shortened version of the Geriatric Depression Scale 
(GDS15) previously validated in Brazil11. 
Clinical data including disease duration, PD treatment and PD 
severity according to the Hoehn and Yahr scale (H&Y)12, the Schwab 
and England scale (S&E)13, and a shortened version of the Unified 
Parkinson’s Disease Rating Scale (UPRDS) previously validated in 
Brazil14 was collected on the same day by a movement disorder specialist. 
Statistical analysis 
Frequency of SAD (overall, primary and secondary) was calculated. 
Student t-test, Mann Whitney, chi-square and Fisher’s exact tests 
were used to compare the continuous and nominal variables 
between patients without SAD versus SAD, and also between 
patients with primary SAD versus secondary SAD. 
Receiver Operating Characteristic (ROC) curves were used to 
determine the best cut-off points in the Mini-SPIN to discriminate 
between subjects with and without SAD according to SCID-I. 
Analysis were performed using the Statistical Package for Social 
Sciences (SPSS for Mac OS X, version 17.0). Normality requirements 
for data distribution were confirmed using Shapiro-Wilk test. A 
significance level of 0.05 was used through. 
Results 
Thirty-four (31%) of the 110 PD patients fulfilled criteria for SAD. 
Half fulfilled criteria for primary SAD (N = 17, 15.5%) and the 
other half fulfilled criteria for secondary SAD. A comparison of 
clinical data of patients without SAD and with SAD and between 
primary and secondary SAD is presented in Table 1. Patients 
with SAD were significantly younger, more frequently in a stable 
relationship, had significantly younger age at PD onset, had worse 
motor symptoms, more depressive symptoms and were more 
frequently depressed. Mini-SPIN score was higher for patients with 
SAD, as expected. No significant differences were found among 
primary and secondary SAD. 
A ROC curve analysis of Mini-SPIN using diagnosis of SAD 
according to SCID-I as gold-standard suggested that a cutoff score 
of 4/5 provided the best balance between sensitivity and specificity. 
This cutoff score provided a sensitivity of 78.8%, a specificity of 70.6%, 
a positive predictive value of 56.5%, and a negative predictive value 
of 87.2%, with an area under the curve of 0.829.
Discussion
It is regularly recommended not to exclude secondary cases of 
mental disorders in PD. The impact of such recommendation in 
clinical practice has been largely studied for depression15 but few 
data exists to support the extension of this recommendation for 
SAD in PD. We found SAD to be more common in PD than what is 
expected in the general population2 when using either the stricter 
or the more general criteria. The frequency of strictly diagnosed 
primary SAD was (15.5%), which is twice higher than that found 
Table 1. Demographic and clinical characteristics of Parkinson’s Disease (PD) patients evaluated for the presence of SAD
Without SAD 
(WS)
SAD p values (WS vs 
SAD)
Primary SAD 
(SAD1)
Secondary SAD 
(SAD2)
p values (SAD1 
vs SAD2)
Number (%) of patients 76 (69.0%) 34 (31%) 17 (15.5%) 17 (15.5%)
Gender % of female 42 (55.3%) 16 (47%) p = 0.43 9 (52.9%) 7 (41.17%) p = 0.49
Age (years), mean ± SD 63.8 ± 11.3 55 ± 13.5 p = 0.001* 56.2 ± 16.1 53.8 ± 10.5 p = 0.61
Marital status, N (%) of married or in a stable relationship 48 (63.2%) 28 (82.4%) p = 0.04* 14 (82.4%) 14 (82.4%) p > 0.999
Employment status, N (%) with paid (formal or informal) work 16 (21.1%) 10 (29.4%) p = 0.34 4 (23.5%) 6 (35.3%) p = 0.45
Years of schooling, mean ± SD 5.8 ± 4.7 5.4 ± 3.1 p = 0.66 4.7 ± 3.2 6.2 ± 2.9 p = 0.12
Disease duration (years), mean ± SD 7.8 ± 5.5 7.4 ± 3.9 p = 0.75 6.2 ± 3.5 8.6 ± 3.9 p = 0.11
Age of disease onset (years), mean ± SD 56.0 ± 12.6 48 ± 13.5 p = 0.002* 49.9 ± 16.6  45.2 ± 9.4 p = 0.62
Most affected side, N (%)
Right
Left
Both
31 (40.7%)
28 (36.8%)
17 (22.3%)
13 (38.2%)
13 (38.2%)
8 (23.5%)
p = 0.97 9 (52.9%)
3 (17.6%)
5 (29.4%)
4 (23.5%)
10 (58.8%)
3 (17.6%)
p = 0.07
Scores on the UPDRS modified motor scale, mean ± SD 8.3 ± 5.4 12.5 ± 7.3 p = 0.003* 10.7 ± 6.7 14.2 ± 7.6 p = 0.16
Schwab and England, mean ± SD 81.5 ± 14.6 78 ± 16.7 p = 0.32 79.4 ± 17.3 76.4 ± 16.5 p = 0.48
Hoehn and  Yahr, mean ± SD 2.0 ± 1.0 2.2 ± 1.1 p = 0.53 2.1 ± 1.1 2.5 ± 1.2 p = 0.39
Presence of motor fluctuation, N (%) 21 (27.6%) 6 (17.6%) p = 0.34 4 (23.5%) 2 (11.7%) p = 0.65
GDS15 total score, mean ± SD 5.0 ± 3.6 8.0 ± 3.8 p < 0.0005* 7.6 ± 3.5 6.6 ± 2.6 p = 0.85
Current depressive episode, N (%) 10 (13.2%) 18 (52.9%) p < 0.0005* 8 (47.1%) 10 (58.8%) p = 0.49
Mini SPIN score, mean ± SD 3.0 ± 2.8 7.1 ± 3.1 p < 0.0005* 7.6 ± 3.5 6.6 ± 2.6 p = 0.32
SAD: Social Anxiety Disorder; UPDRS: Unified Parkinson’s Disease Rating Scale; GDS15: 15 items Geriatric Depression Scale; mini SPIN: mini Social Phobia Inventory; BSPS: Brief Social Phobia Scale; 
SD: standard deviation; *: significant difference (p < 0.05).
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in the general population (7.1%)2. Primary SAD accounted for half 
of the patients with SAD (17 out of 34), which is consistent with a 
previous small study6 in which 7 out of 24 PD patients presented 
SAD (29.2%), of whom 4 (16.6%) had primary SAD. Although our 
data is consistent with previous works it is prudent to consider 
that we used a sample of PD patients from a tertiary referral center 
and that may not be representative of the overall PD population.
Considering the high frequencies of SAD reported and 
the burden of this condition for patients and careers, a more 
targeted and systematic screening should be routinely made in 
clinical practice. Despite being one of the commonest causes of 
psychological morbidity in the general population SAD frequently 
goes unrecognized and undertreated16. Data from the Brazilian 
population indicates that although SAD is present in 10.2% of 
university students only 0.8% (n = 2 out of 235) had ever been 
diagnosed or used medication to treat it17. A possible approach for 
increasing the detection of SAD among PD patients is the broad use 
of self-applicable screening instruments; this can possibly optimize 
diagnosis without increasing medical appointments length and with 
no need for referencing patients to psychiatric evaluation. In our 
sample, using a cut-off score of 4/5, mini-SPIN showed reasonable 
psychometric properties for the screening of SAD in PD. This scale 
is realistic within routine clinical setting and could help point-out 
patients who are suitable for interventions to treat SAD. 
The higher frequency of SAD among PD patients may be 
explained by psychosocial18 and neurobiological mechanisms19. SAD 
may be a psychosocial reaction to the stigmatizing PD symptoms such 
as tremor and bradykinesia, but abnormal function of the striatum 
has been pointed as one of the key pathophysiological mechanism 
implicated in SAD20-23 and it is also plausible that the profound 
disruption of the main catecholaminergic and serotonergic pathways 
that occurs in PD24 predispose patients to SAD. In our sample, SAD 
was associated with the intensity of motor symptoms, younger age 
and with earlier age at disease onset, all of which imply both in higher 
psychosocial stress and in more severe nigrostriatal dopaminergic 
denervation25,26. 
Differentiating primary from secondary SAD might be important 
for clinical practice. It is plausible that primary SAD should be 
benefit from standard treatment for SAD in general population, 
while patients with secondary SAD may benefit from specific 
treatment strategies focused on PD symptoms like optimization 
of antiparkinsonian medications and psychological interventions 
to help patients to cope with PD symptoms with less distress and 
anti-stigma intervention. 
Another issue to be addressed on the association of SAD and PD 
is depression, which is often a comorbidity with PD27,28. Depression 
is known to increase the risk of SAD in general populations and one 
possible explanation for the higher prevalence of anxiety in PD is the 
presence of other mental disorders (such as depression and dementia) 
that might hamper anxiety symptoms evaluation29 or predispose 
the patients to SAD. The co-occurrence of anxiety and depression is 
known to be more common in PD patients than in healthy controls 
or in the general population30. In our sample the PD patients with 
SAD had higher scores in the GDS15 scale and were more likely to 
be depressed. Due to the cross-sectional nature of our study it is not 
possible to explore the nature of the association between SAD and 
depression. 
Conclusion
We conclude that the use of different diagnostic criteria may have 
a massive impact in the estimation of frequency of SAD in PD, 
besides we do not find differences between secondary and primary 
SAD. We also suggest that quick screening questionnaires might 
help guide clinicians in the diagnosis of SAD.
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